Pharmaceutical GMP MRO Catalog Readiness Pattern

Operating context

What the buyer is trying to decide.

Pharmaceutical MRO data quality affects maintenance planning, audit readiness, and controlled change. Duplicate equipment spares with inconsistent descriptions can create avoidable documentation and procurement variance.

Quality HeadMaintenance DirectorCFOProcurement

Control evidence

Methodology appendix
No source-row retention
Owner-attributed reports

Before / after diagnostic posture

The change AI2COE is meant to create inside the buying committee.

Before diagnostic

Compliance postureInconsistent spare descriptions

MaintenanceReview burden during planned shutdowns

ProcurementSupplier and UOM variation

After diagnostic

GMP viewReview backlog grouped by confidence tier

MaintenanceShutdown-critical families prioritized

ProcurementUOM and supplier inconsistencies exposed

Enterprise trust posture

Proof controls buyers expect before they upload operational data.

Source purge Uploaded catalog files are deleted after report generation; only summary metrics and Open Findings remain.

No ERP write-back The diagnostic creates evidence for review. It never changes, deletes, merges, or overwrites ERP records.

Local currency Reports display money in the user's selected or country-derived currency, while USD remains the base audit calculation.

Audit trail Report ownership, access, quota, and feedback events are retained for governed review.

Session downloads Excel, Word, PDF, and CSV downloads are available only in the active generation session.

Open Findings Browser findings remain available without retaining the original source catalog rows.

Buyer interpretation

This is the level of evidence a first paid pilot should produce.

The purpose of a PartsCleanse AI pilot is not to claim instant remediation. It is to create a defensible management fact base: duplicate-family count, confidence distribution, capital exposure, data-readiness issues, and a review sequence that executives can govern.